The co-founders of Fred Hutch's oncology therapeutics developer include Philip Greenberg who previously helped launch Juno Therapeutics.

Affini-T Therapeutics, a US-based cancer therapy spinout of Fred Hutchinson Cancer Research Center, has closed an oversubscribed $175m round featuring the centre itself and The Parker Institute for Cancer Immunotherapy.

Leaps by Bayer, a subsidiary of pharmaceutical and chemicals group Bayer, and life sciences-focused investment firm Vida Ventures, which co-founded Affini-T, co-led the round, which included Alexandria Venture Investments, a vehicle for life sciences and property investment trust Alexandria Real Estate Equities.

Humboldt Fund, Catalio Capital Management, Agent Capital, Erasca Ventures and unnamed others filled out the participants in the round.

Affini-T is developing T cell-driven therapeutics targeting solid tumours. The technology leverages synthetic biology the company claims can work against cancer mutations including those caused by Kirsten rat sarcoma virus – more commonly known as Kras.

Affinit-T’s co-founders include Philip Greenberg, head of immunology at Fred Hutch, who was…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.